[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100499480":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":18,"responsibleParty":35,"collaborators":7,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":50,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":7,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Erik SG Stroes, MD, PhD","Amsterdam UMC, location AMC","PRINCIPAL_INVESTIGATOR",[14],{"name":10,"role":15,"phone":16,"phoneExt":7,"email":17},"CONTACT","+205669111","e.s.stroes@amsterdamumc.nl",[19],{"facility":11,"status":20,"city":21,"state":22,"zip":23,"country":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"RECRUITING","Amsterdam","North Holland","1105 AZ","Netherlands",{"type":26,"coordinates":27},"Point",[28,29],4.88969,52.37403,{"lat":29,"lon":28},[32],{"name":33,"role":15,"phone":34,"phoneExt":7,"email":17},"Erik S. G. Stroes, MD, PhD","+31205669111",{"type":12,"investigatorFullName":36,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"E.S.stroes","Prof. dr. E.S.G. Stroes, MD, PhD.","100499480",false,"NCT05783804","Plaque Reversal With Early, Aggressive Lipid Lowering Therapy","EAGLE","Inclusion Criteria:\n\n* Diagnosed with heterozygous familial hypercholesterolemia\n* Adult between 18 and 50 years old\n* LDL cholesterol levels above 100 mg\u002Fdl (\\>2.6 mmol\u002FL) at inclusion\n\nExclusion Criteria:\n\n* Renal insufficiency, defined as eGFR \\\u003C 30 ml\u002Fmin\n* History of atherosclerotic cardiovascular events\n* Atrial fibrillation\n* Any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator\n* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.","ALL","18 Years","50 Years",{"count":48,"type":49},60,"ESTIMATED","40 Weeks","OBSERVATIONAL","This study evaluates whether plaques in young patients with familial hypercholesterolemia (aged below 50 years) are susceptible to significant plaque regression with early, intensive lipid lowering therapy.",[54],"Coronary Artery Disease Progression","2025-09-30",{"date":57,"type":58},"2025-10-02","ACTUAL",{"date":60,"type":58},"2022-07-07",{"date":62,"type":49},"2027-04",{"name":5,"class":6},1]